» Articles » PMID: 36209983

Mitochondrial Alterations in Fatty Liver Diseases

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2022 Oct 9
PMID 36209983
Authors
Affiliations
Soon will be listed here.
Abstract

Fatty liver diseases can result from common metabolic diseases, as well as from xenobiotic exposure and excessive alcohol use, all of which have been shown to exert toxic effects on hepatic mitochondrial functionality and dynamics. Invasive or complex methodology limits large-scale investigations of mitochondria in human livers. Nevertheless, abnormal mitochondrial function, such as impaired fatty acid oxidation and oxidative phosphorylation, drives oxidative stress and has been identified as an important feature of human steatohepatitis. On the other hand, hepatic mitochondria can be flexible and adapt to the ambient metabolic condition to prevent triglyceride and lipotoxin accumulation in obesity. Experience from studies on xenobiotics has provided important insights into the regulation of hepatic mitochondria. Increasing awareness of the joint presence of metabolic disease-related (lipotoxic) and alcohol-related liver diseases further highlights the need to better understand their mutual interaction and potentiation in disease progression. Recent clinical studies have assessed the effects of diets or bariatric surgery on hepatic mitochondria, which are also evolving as an interesting therapeutic target in non-alcoholic fatty liver disease. This review summarises the current knowledge on hepatic mitochondria with a focus on fatty liver diseases linked to obesity, type 2 diabetes and xenobiotics.

Citing Articles

Motor protein KIF13B orchestrates hepatic metabolism to prevent metabolic dysfunction-associated fatty liver disease.

Miao G, Zhang W, Xu Y, Liu Y, Lai P, Guo J Mil Med Res. 2025; 12(1):11.

PMID: 40038775 PMC: 11877712. DOI: 10.1186/s40779-025-00594-3.


Vitisin A Outperforms Cyanidin-3-O-Glucoside in Triglyceride Reduction by Modulating Hepatic Lipogenesis and Fatty Acid β-Oxidation.

Li Y, Li X, Liu J, Jayavanth P, Bai W, Jiao R Int J Mol Sci. 2025; 26(4).

PMID: 40003987 PMC: 11855501. DOI: 10.3390/ijms26041521.


Alterations of hepatic lipid content following COVID-19 in persons with type 2 diabetes.

Kupriyanova Y, Yurchenko I, Bobrov P, Bartels F, Wierichs S, Jonuscheit M BMJ Open Diabetes Res Care. 2025; 13(1).

PMID: 39965871 PMC: 11836859. DOI: 10.1136/bmjdrc-2024-004727.


Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.

Chu X, Wang X, Feng K, Bi Y, Xin Y, Liu S Lipids Health Dis. 2025; 24(1):55.

PMID: 39962463 PMC: 11831825. DOI: 10.1186/s12944-025-02483-z.


Role of hepatocyte RIPK1 in maintaining liver homeostasis during metabolic challenges.

Zhang W, Liu H, Zhang D, Yi Y, Tao L, Zhu Y Elife. 2025; 13.

PMID: 39886919 PMC: 11785375. DOI: 10.7554/eLife.96798.